The BOXIT trial compared standard treatment and celecoxib (an anti-inflammatory drug) with standard treatment alone for bladder cancer. Celecoxib is a type of drug called a COX-2 inhibitor. COX-2 inhibitors block the action of a protein that may help cancer cells to grow.
We recruited patients with a very early type of bladder cancer called superficial transitional cell bladder cancer. This trial was supported by Cancer Research UK.